Phenylephrine

Introduction Overview

Generic Name

phenylephrine

Brand Name

Nasop12, Sudafed PE, Sudafed PE Children's Nasal Decongestant, Sudafed PE Congestion, Nasop, Sudogest PE, Neo-Synephrine, Ah-Chew D, Despec-SF, Biorphen, Lusonal, Sudafed PE Quick Dissolve, Sudafed PE Extra Strength, Triaminic Thin Strips Nasal Congestion, Triaminic Toddler Congestion Thin Strips, Dimetapp Cold Drops, Triaminic Thin Strips Cold, Triaminic Thin Strips Infant Decongestant, Dimetapp Children's Cold and Allergy, Phenyl-T, PediaCare Children's Decongestant, Vazculep, Phenylephrine Hydrochloride (Eqv-Vazculep), Immphentiv

Dosage Form

oral tablet, extended-release oral tablet, oral liquid, nasal spray, intravenous solution

Drug Class

Decongestants, Vasopressors

Pharmacokinetics

Absorption: Phenylephrine is well absorbed from the gastrointestinal tract following oral administration; however, it undergoes extensive first-pass metabolism in the gut wall and liver primarily via monoamine oxidase enzymes, resulting in low bioavailability. Approximately only 40% of the administered oral dose reaches systemic circulation, limiting its effectiveness as an oral decongestant. Peak plasma concentrations typically occur within 1–2 hours post-dose. Nasal administration bypasses first-pass metabolism allowing for more direct local effects.

Distribution: After absorption, phenylephrine is distributed to various tissues where it acts primarily on alpha-1 adrenergic receptors in vascular smooth muscle. Plasma protein binding is minimal, and volume of distribution is moderate. Phenylephrine's vascular effects are localized predominantly to the nasal mucosa when used as a nasal spray but systemic vascular distribution occurs with intravenous use.

Metabolism: Phenylephrine undergoes extensive metabolism mainly via monoamine oxidase (MAO) in the gastrointestinal wall and liver, transforming it into inactive metabolites. This metabolism significantly limits systemic availability after oral intake. Minor metabolism occurs via conjugation reactions.

Elimination: Phenylephrine and its metabolites are eliminated primarily through renal excretion. Approximately 88% of an oral dose is excreted in urine, mostly as metabolites, with only around 3% recovered unchanged. The elimination half-life after intravenous dosing is approximately 2.5 hours. Renal impairment may alter excretion, necessitating dose adjustments.

Dosage Forms

Available Dosage Forms:
Phenylephrine is available in multiple formulations tailored for different clinical uses. These include:
- Oral tablet (immediate release) typically 10 mg per tablet
- Extended-release oral tablet for prolonged effect
- Oral liquid forms with concentrations such as 160 mg/5 mL, 325 mg/10.15 mL (formulations vary by manufacturer)
- Nasal sprays formulated for topical nasal decongestant effect
- Intravenous solutions used in hospital settings for acute blood pressure support

Dosages for Adults and Adolescents:
- For nasal congestion relief: Adults and children 12 years and older are recommended 10 mg orally every 4 hours, not exceeding 60 mg daily (6 tablets).
- For perioperative hypotension: Initial intravenous bolus doses range from 50 to 250 mcg; maintenance infusion doses range from 0.5 to 1.4 mcg/kg/min titrated to blood pressure targets.
- For vasodilatory shock (e.g. septic shock): Intravenous infusion 0.5 to 6 mcg/kg/min without bolus, titrated to desired hemodynamic response.
- Safety and efficacy in children under 12 years for oral use are not established.

Specific Patient Populations:
- Patients with liver or kidney impairment may require dose adjustments because of altered metabolism and excretion.
- Phenylephrine liquid formulations may contain phenylalanine, requiring caution in patients with phenylketonuria (PKU).
- Injectable forms may contain sodium metabisulfite, requiring caution in patients with sulfite sensitivity or asthma.
- Pregnant and breastfeeding women should use phenylephrine only if clearly needed and under medical supervision due to limited safety data.

Mechanism Of Action

Phenylephrine is a selective alpha-1 adrenergic receptor agonist that exerts its pharmacological effects primarily through stimulation of these receptors located on vascular smooth muscle cells. Upon binding to alpha-1 receptors, phenylephrine activates the Gq protein-coupled receptor pathway which leads to activation of phospholipase C, increasing intracellular inositol triphosphate (IP3) and calcium release from the sarcoplasmic reticulum. Elevated intracellular calcium promotes contraction of vascular smooth muscle, resulting in vasoconstriction.

This vasoconstriction effect reduces blood flow in the nasal mucosa when used topically as nasal spray, thereby decreasing nasal congestion and sinus pressure by limiting fluid leakage and swelling. In systemic administration, such as intravenous infusion, vasoconstriction increases systemic vascular resistance and elevates blood pressure, which is crucial in managing hypotension during anesthesia or shock states. Phenylephrine's selective action on alpha-1 receptors makes it less likely to cause tachycardia compared to non-selective sympathomimetics.

At the cellular level, phenylephrine does not significantly stimulate beta-adrenergic receptors, which accounts for its minimal direct cardiac stimulatory effects. However, reflex bradycardia may occur due to baroreceptor-mediated vagal activation secondary to increased blood pressure. Comparative to pseudoephedrine, phenylephrine shows less effective oral bioavailability and systemic activity due to first-pass metabolism, limiting its clinical efficacy as an oral decongestant.

Multiple clinical studies highlight phenylephrine's efficacy as a nasal spray decongestant with rapid onset of vasoconstriction and symptom relief, though oral formulations face limitations in clinical effectiveness due to low systemic availability. Research continues into understanding phenylephrine's receptor binding affinities and downstream signaling nuances to optimize clinical use and develop improved delivery systems.

Pharmacological Actions

Selective alpha-1 adrenergic receptor agonism inducing vasoconstriction
Nasal mucosal vasoconstriction resulting in reduced nasal congestion
Elevation of systemic vascular resistance to increase blood pressure when used intravenously
Reflex bradycardia due to baroreceptor-mediated vagal stimulation following blood pressure elevation
Minimal beta-adrenergic receptor activity minimizing cardiac stimulation
Reduction of sinus pressure by decreasing blood flow and edema in nasal passages
Use as a vasopressor agent in septic and anesthesia-induced hypotension
Rapid onset of action via nasal route providing symptomatic relief
Weak oral bioavailability due to extensive first-pass metabolism limiting systemic effects
Potential to cause skin blanching and pallor due to peripheral vasoconstriction
May induce hypertensive episodes if overdosed or combined with certain medications
Influences vascular smooth muscle cell calcium signaling to mediate contraction
Produces hemodynamic changes that impact cardiac output and heart rate indirectly
Interaction with sympatholytic and monoamine oxidase inhibitor drugs influencing its pharmacodynamics

Therapeutic Or Clinical Uses

Temporary relief of nasal and sinus congestion caused by colds, allergies, or hay fever when administered as nasal spray or oral formulation
Management of hypotension during spinal or general anesthesia in perioperative settings via intravenous administration
Treatment of vasodilatory shock states, including septic shock, to maintain adequate blood pressure
Adjunct therapy for shock management when volume resuscitation is insufficient
Used as a topical nasal decongestant to reduce nasal mucosal swelling and improve breathing
Support maintenance of blood pressure in critically ill patients requiring vasopressor agents
Alternative to other sympathomimetics in patients with contraindications to beta-agonists
Used in diagnostic settings to evaluate vascular function via induced vasoconstriction
Symptomatic control of nasal congestion in allergic rhinitis cases
Acute symptomatic relief in upper respiratory tract infections involving nasal congestion
Support of hemodynamic stability during cesarean delivery with neuraxial anesthesia
Limited use in pediatric populations, with safety and efficacy yet to be established
Adjunct to anesthesia for maintaining systemic vascular resistance without significant cardiac stimulation
Topical use for nasal decongestant properties with rapid onset and short duration

Side Or Adverse Effects

Flushing characterized by warmth, redness, or tingling sensations
Loss of appetite
Nervousness, agitation, or restlessness, especially notable in pediatric patients
Cardiac arrhythmias including bradycardia, atrioventricular (AV) block, and ventricular extrasystoles
Myocardial ischemia in susceptible individuals with preexisting cardiovascular disease
Nausea and vomiting
Chest pain possibly due to vasoconstriction or extravasation of intravenous administration
Local reactions such as extravasation leading to tissue necrosis
Immune reactions including sulfite sensitivity particularly with injectable forms containing sodium metabisulfite
Headache and tremors
Paresthesias and other nervous system disturbances
Excitability and insomnia
Pulmonary edema and respiratory rales in severe cases
Skin manifestations such as diaphoresis, pallor, piloerection, skin blanching, and necrosis from tissue extravasation
Hypertensive crisis if overdosed or combined with interacting medications

Precautions

Avoid use in patients currently or recently on monoamine oxidase inhibitors (MAOIs) within 14 days due to risk of hypertensive crisis
Use cautiously in patients with cardiovascular disease including hypertension, arrhythmias, or ischemic heart disease
Assess renal and hepatic function prior to use; adjust dosing accordingly in impaired patients
Exercise caution in patients with diabetes mellitus as phenylephrine can affect blood pressure control
Monitor patients with thyroid disorders as vasopressor effects may be exaggerated
Use cautiously in patients with prostatic hypertrophy who have urination difficulties
Phenylephrine liquid contains phenylalanine; avoid or monitor use in patients with phenylketonuria (PKU)
Avoid overuse or prolonged use of nasal sprays to prevent rebound congestion
Be vigilant for allergic reactions, including sulfite sensitivity reactions in susceptible individuals
Avoid concomitant use with other sympathomimetic agents without medical supervision
Pregnant women should only use phenylephrine if clearly needed and under physician supervision
Breastfeeding safety is not established; consider risks and benefits before administration
Use caution in pediatric populations; safety and efficacy not well established in children under 12
If surgery is planned, inform surgeon about current phenylephrine use due to potential intraoperative interactions
Discontinue use and seek medical advice if nervousness, dizziness, severe insomnia, or unresolving symptoms develop

Warnings

Risk of hypertensive crisis especially when administered with monoamine oxidase inhibitors or other interacting drugs
Potential for serious cardiovascular adverse effects including myocardial ischemia, arrhythmias, and reflex bradycardia
Avoid use in the setting of uncontrolled hypertension
Rebound nasal congestion may occur with prolonged or overuse of nasal formulations
Not established as effective oral decongestant; FDA advisory committee has raised concerns about oral efficacy
Risk of serious allergic reactions including anaphylaxis especially with injectable forms containing sulfites
Use with caution in patients with coronary artery disease due to vasoconstrictive properties
Potential for severe headache, blurred vision, or pounding sensations signaling increased blood pressure requiring immediate medical attention
Avoid use in patients with hypersensitivity to phenylephrine or any formulation components
Careful monitoring required in neonates and infants when used off-label or intravenous formulations
Not recommended for use in children under 12 years for oral indication without medical guidance
Possibility of neurological side effects such as restlessness and tremors
Phenylephrine hydrochloride should only be given during pregnancy when clearly needed due to limited data
Injectable preparation extravasation may cause tissue damage and necrosis; monitor IV site closely
Overdose may cause acute hypertensive crisis with cardiovascular and neurologic sequelae

Contraindication

Known hypersensitivity or allergy to phenylephrine or any component of the formulation
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI cessation
Use in patients with severe hypertension
Patients with ventricular tachycardia or severe cardiac disorders without strict monitoring
Avoid use in patients with phenylketonuria (PKU) when using phenylephrine liquid containing phenylalanine
Known sulfite hypersensitivity if using injectable formulations containing sodium metabisulfite
Use contraindicated in patients with narrow-angle glaucoma due to potential vasoconstriction effects
Avoid use concomitantly with other potent vasoconstrictors without appropriate clinical supervision
Intranasal formulations contraindicated in patients with nasal mucosal lesions or trauma
Contraindicated in cases of untreated hyperthyroidism where exacerbation of symptoms may occur
Intravenous phenylephrine contraindicated in patients with bradycardia not controlled by other means
Contraindicated in infants and children under 12 years for oral formulations unless explicitly directed by a physician
Avoid use in patients with severe peripheral vascular disease
Do not use in patients with pheochromocytoma
Contraindicated in the presence of cardiac arrhythmias not controlled or monitored

Drug Interactions

Monoamine oxidase inhibitors (MAOIs) such as phenelzine, tranylcypromine, selegiline, increase risk of hypertensive crisis with phenylephrine
Beta-adrenergic blockers may potentiate vasoconstrictive effects and increase risk of hypertension
Alpha-2 adrenergic agonists like clonidine may have additive vasoconstrictive effects
Steroids can enhance pressor effects of phenylephrine
Tricyclic antidepressants potentiate vasopressor effects and risk of hypertension
Norepinephrine transport inhibitors such as atomoxetine may increase phenylephrine plasma concentrations
Ergot alkaloids including methylergonovine can enhance vasoconstriction leading to ischemic complications
Centrally acting sympatholytic agents such as guanfacine or reserpine may increase risk of hypertensive episodes
Atropine sulfate may interact affecting heart rate and vascular tone
Alpha-adrenergic blockers including phenothiazines like chlorpromazine antagonize phenylephrine action
Amiodarone blocks phenylephrine effects and is itself blocked by phenylephrine
Antihypertensive agents may have altered efficacy when coadministered with phenylephrine
Other vasoconstrictors increase the risk of severe hypertension and cardiovascular adverse events
Drugs that induce uterine contractions (oxytocic drugs) can augment phenylephrine's pressor activity
Co-administration with sympathomimetics or stimulants increases risk of cardiovascular adverse effects

Preparations Of The Drug

Oral immediate-release tablets, typically 10 mg strength utilized for nasal congestion
Extended-release oral tablets designed for prolonged symptom control
Oral liquid formulations with variable concentrations, inclusive of phenylalanine for certain formulations
Nasal sprays for topical decongestion with rapid onset of action
Intravenous preparations for hospital use to support blood pressure during anesthesia or shock
Chewable tablets for pediatric nasal decongestion formulations such as Ah-Chew D
Orally disintegrating tablets that dissolve rapidly without need for water ingestion
Preparations with and without phenylalanine to accommodate patients with PKU
Intravenous formulations containing sodium metabisulfite as preservative, with allergy warnings
Combination products containing phenylephrine and other cold or allergy medications (e.g. Sudafed PE Congestion)
Various branded and generic formulations manufactured by multiple pharmaceutical companies including Johnson & Johnson Consumer Inc., Hikma Pharmaceuticals, Nuvicare LLC, Cantrell Drug Company, and Rugby Laboratories
Topical nasal sprays available in over-the-counter and prescription strengths
Phenylephrine injection products approved for use as vasopressor agents in intensive care and surgical settings
Liquid drops designed for pediatric use such as Dimetapp Cold Drops and PediaCare Children's Decongestant
Strip formulations for pediatric nasal congestion such as Triaminic Thin Strips